双靶点CAR T细胞疗法TriPRIL在复发难治性多发性骨髓瘤中显示初步疗效
Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma
Mass General Brigham研究团队在The Lancet发表的一项I期临床试验显示,靶向BCMA和TACI的双靶点CAR T细胞疗法TriPRIL在15名复发或难治性多发性骨髓瘤患者中的总体响应率达80%,其中53%达到完全缓解。9名曾接受BCMA CAR T治疗后进展的患者中亦有应答,安全性良好,未出现严重细胞因子释放综合征或神经毒性,目前已规划II期试验。
原文报告15例I期研究的初步数据,双靶点CAR T细胞疗法在三联治疗失败患者中仍取得较高响应率。
A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL—short for trimeric APRIL (a proliferation-inducing ligand)—recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet.
Targeting two proteins on myeloma cells
Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient's T cells so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation antigen (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI).
Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.
"BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse," said co-senior author Marcela V. Maus, M.D., Ph.D., director of the Mass General Brigham Cancer Institute's Cellular Immunotherapy Program. "TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA."
Responses after prior treatment failures
The Phase I TriPRIL trial treated 15 patients at the Mass General Brigham Cancer Institute whose multiple myeloma had come back despite many treatments. Nine patients had previously received BCMA-directed CAR T-cell therapy but saw their cancer progress. Twelve of the 15 patients (80%) responded, meaning cancer signs fell by at least half. In eight (53%), blood, urine and bone marrow tests found no signs of active myeloma.
TriPRIL cells remained detectable in some patients' blood beyond six months after treatment. The treatment was also relatively safe, with no severe cases of cytokine release syndrome or neurotoxicity.
"Seeing this new treatment work in patients whose cancer had returned after treatment targeting BCMA stood out," Maus said. "It was also encouraging that the patients we tested showed no immune reaction against TriPRIL."
Because the study included only 15 patients and followed them for a relatively short time, researchers need larger, longer studies to determine how long the benefits last and identify less common side effects. They are planning a Phase II trial with more patients and longer follow-up.
Publication details
Benjamin R Puliafito et al., Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial, The Lancet (2026). DOI: 10.1016/s0140-6736(26)01806-4
Journal information: The Lancet
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-dual-car-cell-therapy-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com